About i3 Prism
i3 Prism is an early-stage technology commercialization fund focused on women and Black, Indigenous and People of Color (BIPOC) healthcare innovators who aim to bring new healthcare solutions to patients and society, and advance technologies to the next level from a commercial perspective. Selected applicants will receive up to $33K in funding, which will be distributed based on the achievement of milestones.
How it Works
Innovators seeking to develop their technology with the potential for commercialization can submit to the i3 Prism Request for Proposals (RFP) until Tuesday, March 5. Applicants must also disclose the technology to MSIP. The submitted proposals will be distributed for review among Mount Sinai experts in fields including medical devices, digital health, and therapeutics. Applications will be judged and scored based on project feasibility and market risks against the budget and milestones provided. Recorded scores from the reviewers will be pulled and tabulated by members of an internal working group and the awardees will be selected. When the awardees are notified and have signed an Informed Participation Letter (IPL), fund accounts will be created and funding will be disbursed.
Are you interested in being considered for i3 Prism and have not disclosed the technology? Disclose here.
February 5i3 Prism RFP period opens
March 5RFP period ends
March - AprilRFP review by Mount Sinai experts
Late AprilAwardees selected
MayAwardees notified of selection
JuneAwardees sign IPL, finalize project plans, and budget
JulyProject execution begins (pending the IPL signing and finalization of plans and budget)
Eligible applicants must:
How to Apply
The RFP period for 2024 is open until Tuesday, March 5.